{"id":7186,"date":"2013-06-04T04:59:31","date_gmt":"2013-06-04T08:59:31","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7186"},"modified":"2013-06-04T04:59:31","modified_gmt":"2013-06-04T08:59:31","slug":"clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186","title":{"rendered":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Clovis Oncology Inc (NASDAQ:CLVS) had surged by more than 100 percent owing to the successful preliminary testing results of its drug for treating ovarian cancer. The shares of the bio pharmaceutical company had increased by 103.91 percent to close at $74.59 per share for the trading session on Monday. The shares of Clovis Oncology Inc (NASDAQ:CLVS) had opened at $50.00 per share and had been trading in the range of $50.00 to $86.29 per share during the day, before closing at $38.01 higher than the previous close on Friday.<\/p>\n<p style=\"text-align: justify;\"><b>Preliminary results of ovarian cancer drug<\/b><\/p>\n<p style=\"text-align: justify;\">Clovis Oncology Inc (NASDAQ:CLVS), with its operations based in United States and involved in developing anti cancer drugs, had announced the preliminary results for its development stage drug for treating ovarian cancer. The results of preliminary tests had been highly successful and had thereby pushed the shares of Clovis Oncology Inc (NASDAQ:CLVS) to hit new 52 week high price levels at $86.29 per share. This surge proves to be highly encouraging for the preliminary results, as the drug still has a long way to go on with the Phase I and Phase II clinical trials.<\/p>\n<p style=\"text-align: justify;\">The shares of Clovis Oncology Inc (NASDAQ:CLVS) had witnessed heavy trading volume on Monday with nearly 3.22 million shares being exchanged hands, while the average trading volume of the company is at 197,855 shares per day. The bio pharmaceutical company presently holds 26.27 million shares outstanding in the market and the institutional ownership is at 73 percent of its holdings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Clovis Oncology Inc (NASDAQ:CLVS) had surged by more than 100 percent owing to the successful preliminary testing [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":7187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2436,2437],"stock_ticker":[],"class_list":["post-7186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-clovis-oncology-inc-nasdaqclvs","tag-nasdaqclvs","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Clovis Oncology Inc (NASDAQ:CLVS) had surged by more than 100 percent owing to the successful preliminary testing [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-04T08:59:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug\",\"datePublished\":\"2013-06-04T08:59:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg\",\"keywords\":[\"Clovis Oncology Inc (NASDAQ:CLVS)\",\"NASDAQ:CLVS\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\",\"name\":\"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg\",\"datePublished\":\"2013-06-04T08:59:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186","og_locale":"en_US","og_type":"article","og_title":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR","og_description":"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Clovis Oncology Inc (NASDAQ:CLVS) had surged by more than 100 percent owing to the successful preliminary testing [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-04T08:59:31+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug","datePublished":"2013-06-04T08:59:31+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg","keywords":["Clovis Oncology Inc (NASDAQ:CLVS)","NASDAQ:CLVS"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186","url":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186","name":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg","datePublished":"2013-06-04T08:59:31+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Vials_Zaldylmg_Flickr_02222012.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/clovis-oncology-inc-nasdaqclvs-announced-its-preliminary-results-of-ovarian-cancer-drug-7186#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Clovis Oncology Inc (NASDAQ:CLVS) announced its Preliminary results of ovarian cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7186"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7186\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7187"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7186"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}